Double-blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline

British Journal of Clinical Pharmacology

Volumn 42, Issue 4, 1996, Pages 491-498

  Edwards, J Guy ^a   Dinan, Timothy G ^b   Waller, Derek G ^c   Greentree, Stephen G ^d  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d Clinical Research Department   (United Kingdom)

Author keywords

amitriptyline; depression; efficacy; electrocardiography; minaprine; safety; systolic time intervals; unwanted effects

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; MINAPRINE;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0029795235     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00013.x     Document Type: Article

References (41)

1. Wermuth CG, Exinger A. Le dichlorhydrate de la morpholinoethylamino-3-methy-4-phenyl-6-pyridazine. Agressologie 1972; 13: 285-289.
2. Bizière K, Kan JP, Goniot S, Wermuth CG. Neurochemical profile of a novel psychotropic drug. J Neurochem 1983; 41: 78-82.
3. Kan JP, Baudry N, Bougault I, Gonalons S, Garratini S. Effets de la minaprine (Cantor®) sur la transmission dopaminergique centrale chez le rongeur. Acta Pharm Biol Clin 1983; 2: 137-142.
4. Ferreti P, Algeri S, Benefati F, Cimino M, Ferreti L. Chemical effects of minaprine on striatal dopaminergic neurons in rats. J Pharm Pharmacol 1984; 36: 48-52.
5. Garattini SM Forloni GL, Tirelli AS, Ladinski H, Consolo S. Neurochemical effect of minaprine, a novel psychotropic drug, on the central cholinergic system of the rat. Psychopharmucology 1984: 82: 210-215.
6. Worms P, Kan JP, Steinberg R, Terranova J-P, Perio A, Bizière K. Cholinomimetic activities of minaprine. Arch Pharmacol 1989; 340: 411-418.
7. Davi H, Dupont P, Jeanniot JP, Roncucci R, Cautreels W. The biotransformation of 14C-minaprine in man and five animal species. X enobiotica 1985; 15: 97-106.
8. Crocq L, Fondarai J, Haniin B. The place of minaprine in general practice. Psychol Med 1982; 14: 1097-1116.
9. Mariani E, Francheschi M, Minicucci F, Strambi LF, Smirne S. Therapeutic efficacy of minaprine and nomifensine in neurotic depression. Clin Neurol 1983; 4: 165-168.
10. Mikus P, Bizière K, Bentel U. A controlled study of minaprine and nomifensine in outpatients with masked depression. Clin Trials J 1985; 22: 477-488.
11. Radmayr E, Bizière K, Bentel U. Minaprine and maprotiline in endogenous depression: A double-blind controlled study. Clin Trials J 1986; 23: 100-109.
12. Bohacek N, Ravic M, Bizière K. Minaprine and imipramine in the treatment of major depressive disorders. A comparative double-blind study. Drugs Exp Clin Res 1987; 7: 435-442.
13. Montgomery SA, Baldwin DS, Priest RG, et al. Minaprine and dose response in depression: An investigation of two fixed doses of minaprine compared with imipramine. Pharmacopsychiatry 1991; 24: 168-174.
14. Wheatley D. Minaprine in depression. A controlled trial with amitriptyline. Br J Psychiat 1992; 161: 113-115.
15. Smirne S, Mariani E, Tancredi D, Francheschi M, Canal N. Effects of minaprine on sleep, anxiety and cognitive functions. Clin Trials J 1985; 22: 187-200.
16. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorder. 3rd Edition Revised. Washington DC, American Psychiatric Association, 1987: 218-224.
17. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
18. Cleary P, Guy W. Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1977; 1: 115-120.
19. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psvchiat 1979; 134: 382-389.
20. Bazett HC An analysis of the time-relationship of electrocardiograms. Heart 1920; 7: 353-370.
21. Lewis RP, Rittgers SE, Forester WF, Boudoulas H. A critical review of systolic time intervals. Circulation 1977; 56: 146-158.
22. Sundberg S. Influence of heart rate on systolic time intervals. Am J Cardiol 1986; 58; 1144-1145.
23. Cochrane WG, Cox GM (1957). Experimental Designs. 2nd Edition. New York. Wiley. 1957.
24. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Ass 1955; 50: 1096-1121.
25. Edwards JG. Ethics of placebo-controlled trials in depression. Human Psychopharmacol 1989; 4: 235-236.
26. Jouvent R, Lancrenon S, Patay M, Widlocher D. A controlled trial of minaprine versus placebo in inhibited depressed outpatients. In Recent Advances in Psychiatric Treatment, First European Conference 1984; p3.
27. Amsterdam JD, Dunner DL, Fahre LF, Kiev A, Rush AJ, Goodman LI. Double-blind, placebo controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiat 1989; 22: 137-143.
28. Montgomery SA, McAuley R, Rani SJ, Roy D, Montgomery D. A double blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand 1981; 63 (suppl. 290): 314-327.
29. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed dose fluoxetine therapy of depression. Psychopharmacol Bull 1987; 23: 164-168.
30. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M. Low dose fluoxetine therapy for depression. Psychopharmacol Bull 1988; 24: 183-188.
31. Blackwell B. Adverse effects of antidepressant drugs. 1. Monoamine oxidase inhibitors and tricyclics. Drugs 1981; 21:201-219.
32. Cassem N. Cardiovascular effects of antidepressants. J Clin Psychiat 1982; 43: 22-28.
33. Risch SG, Groom GP, Janowsy DS. The effects of psychotropic drugs on the cardiovascular system. J Clin Psychiat 1982; 43: 16-31.
34. Veith RC, Raskind MA, Caldwell JH, Barnes RF, Gumbrecht G, Ritchie JL. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med 1982; 306: 954-959.
35. Upward JW, Edwards JG, Goldie A, Waller DG. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol 1988; 26: 399-402.
36. Sacks MH, Bonforte RJ, Lasser RP, Dimich f. Cardiovascular complications of imipramine intoxication. JAMA 1968; 205: 588-590.
37. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. Br Med J 1987; 295: 1021-1024.
38. Nemec J. Cardiotoxic effects of tricyclic antipsychotics. Toxicol Exp 1973; 4-5: 224-231.
39. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiat 1985; 46: 424-444.
40. Burgess CD, Montgomery S, Wadsworth J, Turner P. Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients. Postgrad Med J 1979; 55: 704-708.
41. Burgess CD, Turner P. Cardiovascular effects of antidepressants; clinical implications. In Stress and the Heart, ed. Wheatley D, New York, Raven: 1981: pp173-190.